The Clinical Protocol Scientific Review and Monitoring System (PRMS) was fully approved by the NIH/NCI on December 16, 1996. The PRMS provides an initial review for scientific merit and feasibility for every protocol not sponsored by an NCI-sponsored national cooperative group. The PRMS also reviews protocol-specific data and safety monitoring plans and revisions of previously approved investigator-initiated protocols. The PRMS does not provide an auditing or monitoring function, but receives reports from the Data and Safety Monitoring Committee (DSMC) as well as any active independent Data and Safety Monitoring Boards (DSMBs). In order to facilitate cooperation and share information, the PRMS sends minutes to the IRB and receives both the IRB agenda and IRB minutes. This exchange allows the PRMS to monitor submissions to the IRB to ensure that appropriate protocols that have not received PRMS approval are not reviewed by the IRB. The PRMS coordinator also queries the IRB's database monthly to track protocol progress and ensure current data. The System is coordinated by a full time Program Coordinator, currently supported 50% by the CCSG. Because the review requirements and database support have increased since the last renewal, we request an increase to 80% salary support for Catherine Reniere (Program Coordinator) and continued support at 10% for James Larner, MD (PRMS Chair), as well as the $1,000 for supplies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-18
Application #
7726792
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-02-01
Budget End
2009-01-31
Support Year
18
Fiscal Year
2008
Total Cost
$31,697
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Knapp, Kiley A; Pires, Eusebio S; Adair, Sara J et al. (2018) Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. Oncotarget 9:8972-8984
Kedzierska, Katarzyna Z; Gerber, Livia; Cagnazzi, Daniele et al. (2018) SONiCS: PCR stutter noise correction in genome-scale microsatellites. Bioinformatics 34:4115-4117
Zhang, Xuewei; Kitatani, Kazuyuki; Toyoshima, Masafumi et al. (2018) Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer. Mol Cancer Ther 17:50-59
Cruickshanks, Nichola; Zhang, Ying; Hine, Sarah et al. (2018) Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma. Clin Cancer Res :
Balogh, Kristen N; Templeton, Dennis J; Cross, Janet V (2018) Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses. PLoS One 13:e0197702
Gonzalez, Phillippe P; Kim, Jungeun; Galvao, Rui Pedro et al. (2018) p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression. Glia 66:999-1015
Rodriguez, Anthony B; Peske, J David; Engelhard, Victor H (2018) Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma. Methods Mol Biol 1845:241-257
Stowman, Anne M; Hickman, Alexandra W; Mauldin, Ileana S et al. (2018) Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Res 28:237-245
Melhuish, Tiffany A; Kowalczyk, Izabela; Manukyan, Arkadi et al. (2018) Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression. Biochim Biophys Acta Gene Regul Mech 1861:983-995
Kulling, Paige M; Olson, Kristine C; Olson, Thomas L et al. (2018) Calcitriol-mediated reduction in IFN-? output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation. J Steroid Biochem Mol Biol 177:140-148

Showing the most recent 10 out of 539 publications